New York approves PreciseDx's AI breast cancer diagnostic

Pathology slides under a microscope have long been considered the gold standard for cancer diagnoses. Yet even for the most seasoned specialists, reading tissue patterns still involves a degree of subjective interpretation.

PreciseDx wants to replace that guesswork with cold, hard algorithmic measurements.

The digital pathology company announced that its AI-powered breast cancer test, PDxBr, secured clinical and analytical validation from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP). The clearance allows PreciseDx's CLIA-certified laboratory to begin processing real-world patient samples.

Quantifying what pathologists see

The PDxBr test relies on array morphology to deliver reproducible, objective data from invasive breast cancer tissue specimens.

PreciseDx CEO Wayne Brinster noted that the diagnostic platform has proven to be an effective prognostic tool, refining risk stratification beyond what traditional histopathology methods offer. According to the company, providing quantifiable data gives oncologists a far more robust readout of a patient's disease status.

Crucially for state regulators, the test's morphology metrics proved reliably reproducible across patient cohorts, paving the way for its official green light.

From manual charts to automated workflows

The approval comes as healthcare providers increasingly lean on AI to cut through administrative lag in oncology care.

At HCA Healthcare, tracking down newly diagnosed cancer patients used to mean nurses manually digging through lab results, physician schedules, and paper referrals. Once the network deployed an AI tool to surface positive cancer findings directly from pathology and radiology reports into its Meditech EHR system, things shifted fast.

Kristina Rua, former director of oncology navigation services at HCA's East Florida division, reported that the AI workflow shaved six full days off the time from diagnosis to a patient's first treatment, while boosting patient retention by 15%.

Similarly, Mayo Clinic's Dr. Tufia Haddad highlighted during a HIMSS session that algorithmic matching for clinical trials yielded immediate efficiency gains, ultimately freeing up clinicians to spend more direct face-time with patients.

Why it matters

We see PreciseDx's regulatory milestone as another sign that AI pathology is finally crossing the bridge from research experiments into commercial healthcare operations.

Getting cleared under CLEP and operating within a CLIA-certified lab means the algorithm isn't just an experimental dashboard widget. It is now part of the formal diagnostic pipeline, directly shaping patient care decisions.

For clinicians, sharper risk stratification in invasive breast cancer can help prevent both under-treatment and the grueling side effects of over-treatment. It gives oncologists objective numbers to back up delicate prognostic choices.

Still, the hurdle moving forward will be institutional adoption. PreciseDx now has to prove that busy hospital pathology departments are willing to change their existing routines—and that insurers will willingly reimburse an algorithm-assisted bill.